According to a pooled analysis of 16 randomized trials published in Psychiatric Times, 2024, remission occurred in 31% of patients who received an adjunctive antipsychotic for major depression, compared to just 17% of those on placebo alone. That is nearly double the remission rate, without switching antidepressants.
If your antidepressant has not brought you back to yourself, you are not alone, and you are not out of options. A large and growing body of evidence supports the use of antipsychotics for depression as an add-on strategy, not a replacement, when standard treatment falls short. This article explains how that works, which medications have FDA approval, and what realistic expectations look like.
Why Would an Antipsychotic Help With Depression?
Antipsychotic medications for depression work because depression is not a single-mechanism disorder. While antidepressants primarily target serotonin and norepinephrine, many people with hard-to-treat depression also have dysregulation in the dopamine system, which antidepressants do not directly address.
Atypical antipsychotics act on both dopamine and serotonin receptors, filling a therapeutic gap that antidepressants leave open. When added to an existing antidepressant, they can restore signaling balance in brain circuits tied to motivation, emotional processing, and reward, areas that serotonin-focused medications often miss.
This is why psychiatrists describe the strategy as augmentation: the antipsychotic is not replacing the antidepressant but amplifying its effect.
Which Antipsychotics Are FDA-Approved for Depression?
Approved Medications at a Glance
Not all antipsychotic drugs for depression carry the same level of regulatory support. The following medications have received specific FDA approval as adjunctive (add-on) therapy for major depressive disorder:
Medication | Brand Name | FDA Approval Year |
Aripiprazole | Abilify | 2007 |
Quetiapine XR | Seroquel XR | 2009 |
Olanzapine + fluoxetine | Symbyax | For TRD specifically |
Brexpiprazole | Rexulti | 2015 |
Cariprazine | Vraylar | 2023 |
Antipsychotics and Depression: What the Latest Research Shows
According to the American Journal of Psychiatry, aripiprazole was the first antipsychotic to receive FDA adjunctive MDD approval and remains one of the most studied. Cariprazine received its MDD indication most recently, in 2023, based on strong Phase 3 trial data.
A 2026 network meta-analysis reviewed 22 randomized trials involving over 10,900 adults and found that lumateperone and aripiprazole showed the strongest results for symptom response among adjunctive antipsychotics, per Medscape’s review of the findings.
What Is the Best Antipsychotic for Depression?
How Psychiatrists Match Medication to Symptom Profile
There is no single best antipsychotic for depression that works for every patient. The right choice depends on the specific symptom profile, existing medication, and the side effects a person can tolerate.
Here is how psychiatrists typically think through the options:
- Aripiprazole tends to be the first choice for patients who need motivation and energy restored, as it carries a lower sedation and weight-gain burden than older options.
- Quetiapine XR is often preferred when sleep disturbance and anxiety are prominent, given its sedating profile at lower doses.
- Brexpiprazole has a similar mechanism to aripiprazole with a somewhat lower akathisia (restlessness) risk, making it better tolerated by some patients.
- Cariprazine shows particular promise when low energy, low motivation, and blunted emotion are the dominant symptoms.
- Olanzapine (combined with fluoxetine as Symbyax) is specifically approved for treatment-resistant depression but carries the highest metabolic risk of the group.
Why Switching Is Normal, Not a Setback
The goal is always the minimum effective dose with the best tolerability for that individual. Switching between options is common and does not indicate failure.
Patients at Good Health Psych who have not responded fully to antidepressants can discuss augmentation options through a medication management evaluation, where the full picture of their treatment history is reviewed before any changes are made.
Do Antipsychotics Actually Help With Depression?
The short answer: yes, for a meaningful subset of patients, they do. The more complete answer is that the evidence is strong but nuanced.
A large-scale study of over 244,000 patients with depression found that 7% received a second-generation antipsychotic as an augmenting agent, making it one of the most common add-on strategies in real-world practice. For patients with antipsychotics for treatment-resistant depression, defined as failing at least two adequate antidepressant trials, the evidence is especially compelling.
That said, augmentation is not a universal solution. Roughly one-third of patients in clinical trials experience remission with this approach. The others may see partial improvement, need a different antipsychotic, or benefit more from an alternative strategy such as TMS therapy or Spravato (esketamine) treatment.
Antipsychotic augmentation is not a last resort. It is a legitimate second-line option, often introduced after one antidepressant has produced partial but insufficient benefit.
Risks and Side Effects: What to Weigh
Side Effects Most Relevant at Depression Doses
The most clinically relevant side effects for this class when used at the lower doses typical of depression augmentation:
- Weight gain and metabolic changes: Most pronounced with olanzapine and quetiapine. Aripiprazole, brexpiprazole, and cariprazine are considered metabolically lighter options.
- Akathisia (inner restlessness): Most associated with aripiprazole at higher doses. Often dose-dependent and manageable with adjustment.
- Sedation: Common with quetiapine, which can be a benefit or a drawback depending on the patient’s sleep situation.
- Blood sugar and cholesterol shifts: Relevant over the longer term; routine bloodwork is standard practice.
Why Tolerability Is Manageable for Most Patients
The important context: at the low doses used for depression augmentation, many patients tolerate these medications well. Side effects are real, but they are also manageable, and the clinical priority is always to match the medication profile to the patient’s specific vulnerabilities.
For patients managing depression alongside other conditions, close monitoring during the first 4 to 6 weeks is standard at Good Health Psych, with telehealth check-ins available between office visits.
What to Expect When Starting Augmentation
- Week 1-2: Some patients notice improvements in sleep and anxiety fairly quickly, particularly with quetiapine. Core mood changes take longer.
- Weeks 3-6: The clearest window for assessing whether the augmentation is working. Persistent flatness or worsening should be flagged with your prescriber.
- Month 2-3: If the medication is helping, a conversation about optimal dose and duration begins. Most guidelines recommend continuing for at least 6-12 months after remission.
- Ongoing: Regular metabolic monitoring (weight, fasting glucose, lipids) is part of responsible long-term management.
Starting an antipsychotic for depression does not mean taking it forever. Many patients use augmentation for a defined period, stabilize, and then taper off with their psychiatrist’s guidance.
If antidepressants alone have not been enough, there may be a better combination waiting. Schedule an appointment at Good Health Psych to speak with a board-certified psychiatrist, often available same day or next day, and review your full treatment picture.
FAQ
Yes. Several antipsychotic medications are FDA-approved specifically as add-ons for non-psychotic major depressive disorder. Psychosis is not required or even common among patients who benefit from this approach.
Some improvement in sleep or anxiety can appear within the first one to two weeks. Meaningful changes in mood, motivation, and energy typically take four to six weeks. Remission, when it occurs, is usually visible by the eight-week mark.
No. FDA-approved antipsychotic medications for depression are adjunctive, meaning they are added to an existing antidepressant, not used in its place. The combination targets different brain systems simultaneously.
Treatment-resistant depression is generally defined as major depression that has not responded adequately to at least two different antidepressant trials. Antipsychotic augmentation is one of the most evidence-backed strategies for this group, alongside options like TMS and esketamine.
Not without guidance. Feeling better is a sign the treatment is working, not a signal to stop. Tapering should be done gradually and under medical supervision to avoid rebound symptoms.
That depends on how many antidepressant trials you have had, how you responded, and what symptoms remain. A full psychiatric evaluation is the right starting point, not a checklist. A board-certified psychiatrist can review your history and discuss whether augmentation is worth exploring.